--Two clinical trials suggest promise for using these medications in combination with other cancer therapies Two clinical trials using combinations of drugs meant to change cancer epigentics —or the way tumors express genes — failed at shrinking colon and breast tumors. However, these trials open the door for others currently in the works to combine […]
Research
How common is prostate cancer?
Posted by admin | ResearchProstate cancer is extremely common in the U.S. “It’s the most common life-threatening cancer in men, responsible for 26,000 deaths per year,” says William G. Nelson, M.D., Ph.D., director of the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins. But there are a lot of prostate cancers that are not life-threatening, he says. “In autopsies […]
Jun 29, 2017 No comments
Stefanie Joho describes how she participated in a landmark clinical trial of immunotherapy
Posted by admin | ResearchWhen doctors told Stefanie Joho that they had no options left, her sister scoured the internet to find "something" that could offer hope. She found a clinical trial at Johns Hopkins that looked promising, and little did Stefanie know that it would transform her life and become FDA approved. Listen to Stefanie tell her story:
May 26, 2017 No comments
Top Maryland scientists discuss research on tracking and treating cancer
Posted by admin | ResearchAt the annual Research Matters conference yesterday, top scientists from the Johns Hopkins Kimmel Cancer Center and University of Maryland Greenebaum Cancer Center discussed research using advanced imaging methods to develop better ways pinpoint and track cancer cells — down to the microscopic level — and precisely target each cell with anti-cancer drugs. Experts also delivered presentations […]
Apr 13, 2017 No comments

Johns Hopkins Student Wins Top Prize For Research on Lethal Brain Tumors in Children
Posted by admin | Childhood Cancer, ResearchJohns Hopkins undergraduate student Sabrina Wang won first place in a competition among 125 students for her research on a lethal type of pediatric brain tumor called atypical teratoid/rhabdoid tumors (AT/RT), the most common brain tumor type in infants. The award was presented at the AACR 2017 annual meeting in Washington, D.C., on April 2. […]
Apr 5, 2017 No comments

Top Questions Ahead for Cancer Immunotherapy
Posted by admin | ResearchA decade ago, Suzanne Topalian, M.D., led a team of researchers who made an astonishing contribution to how cancer is fought. Many cancers can “put the brakes” on the body’s immune cells — cells that would normally storm into a tumor and destroy it. Topalian, director of the Melanoma Program at the Johns Hopkins Kimmel […]
Feb 14, 2017 4 comments
Research from Bloomberg-Kimmel Institute Among Best of #ASCO2017
Posted by admin | ResearchMore than 20 years ago, when Johns Hopkins scientists Bert Vogelstein, Ken Kinzler and their colleagues linked certain cancers to mutations in genes that repair DNA, they may not have imagined that their findings would spark an idea that has become a crystal ball for predicting whether immunotherapy is more likely to work in a person […]
Feb 1, 2017 No comments
What’s next for bladder cancer research?
Posted by admin | ResearchThe Johns Hopkins Greenberg Bladder Cancer Institute recently announced a joint effort with the Bladder Cancer Advocacy Network (BCAN) to fund up to two awards totaling $100,000 for young scientists. As part of the announcement, the Institute's director, David McConkey, Ph.D., gave us his thoughts on recent bladder cancer advances and ongoing research. Recent advances, says McConkey, include […]
Jan 20, 2017 No comments
Scientists let GENIE data “out of the bottle”
Posted by admin | ResearchNearly 19,000 de-identified genomic records from cancer patients treated by an international group of hospitals, including the Johns Hopkins Kimmel Cancer Center, have been collected in a database coordinated by the American Association for Cancer Research (AACR) and are now available to scientists across the globe. The data was gathered from the genomic sequencing of […]
Jan 17, 2017 No comments
5 Things We Learned About Immunotherapy This Year
Posted by admin | ResearchImmunotherapy has become one of the hottest areas of cancer research, and the number of cancers successfully treated by immunotherapy is growing. Nearing the end of 2016, there are now four FDA-approved immunotherapy drugs that target immune system checkpoints to treat six types of cancer. We asked Drew Pardoll, M.D., Ph.D., director of the Bloomberg~Kimmel […]
Dec 27, 2016 3 comments